SG10201500013SA - Methods for use of a specific anti-angiogenic adenoviral agent - Google Patents

Methods for use of a specific anti-angiogenic adenoviral agent

Info

Publication number
SG10201500013SA
SG10201500013SA SG10201500013SA SG10201500013SA SG10201500013SA SG 10201500013S A SG10201500013S A SG 10201500013SA SG 10201500013S A SG10201500013S A SG 10201500013SA SG 10201500013S A SG10201500013S A SG 10201500013SA SG 10201500013S A SG10201500013S A SG 10201500013SA
Authority
SG
Singapore
Prior art keywords
methods
specific anti
angiogenic
adenoviral agent
agent
Prior art date
Application number
SG10201500013SA
Other languages
English (en)
Inventor
Yael Cohen
Naamit Sher
Erez Feige
Livnat Bangio
Eyal Breitbart
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of SG10201500013SA publication Critical patent/SG10201500013SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201500013SA 2010-01-05 2011-01-05 Methods for use of a specific anti-angiogenic adenoviral agent SG10201500013SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28222810P 2010-01-05 2010-01-05
US28224710P 2010-01-07 2010-01-07

Publications (1)

Publication Number Publication Date
SG10201500013SA true SG10201500013SA (en) 2015-03-30

Family

ID=44305892

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201500013SA SG10201500013SA (en) 2010-01-05 2011-01-05 Methods for use of a specific anti-angiogenic adenoviral agent
SG2012049581A SG182367A1 (en) 2010-01-05 2011-01-05 Methods for use of a specific anti-angiogenic adenoviral agent

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012049581A SG182367A1 (en) 2010-01-05 2011-01-05 Methods for use of a specific anti-angiogenic adenoviral agent

Country Status (11)

Country Link
US (3) US9567605B2 (enExample)
EP (2) EP2521776B1 (enExample)
JP (2) JP6196040B2 (enExample)
KR (1) KR101754437B1 (enExample)
AU (1) AU2011204405B2 (enExample)
CA (1) CA2786374C (enExample)
DK (2) DK2521776T3 (enExample)
MX (1) MX342641B (enExample)
NZ (1) NZ601324A (enExample)
SG (2) SG10201500013SA (enExample)
WO (1) WO2011083464A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
MXPA04003514A (es) 2001-10-19 2004-07-23 Vascular Biogenics Ltd Construcciones de polinucleotidos, composiciones farmaceuticas y metodos para reducir la regulacion dirigida de angionesis y terapia anticancer.
EP2051988A4 (en) 2006-07-31 2010-06-02 Vascular Biogenics Ltd POLYPEPTIDES AND THESE CODING POLYNUCLEOTIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES RELATED TO ISCHEMIA
JP6151515B2 (ja) 2010-01-05 2017-06-21 バスキュラー バイオジェニックス リミテッド 神経膠芽腫ｇｂｍを治療するための組成物および方法
EP2521776B1 (en) * 2010-01-05 2016-11-02 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
HUE042262T2 (hu) * 2012-10-17 2019-06-28 Vascular Biogenics Ltd FAS-kimérát kifejezõ adenovírus és alkalmazása rákkezelési módszerekben
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
WO2014118643A2 (en) 2013-02-04 2014-08-07 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
CA2968790A1 (en) 2014-11-26 2016-06-02 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
WO2019077593A1 (en) 2017-10-20 2019-04-25 Vascular Biogenics Ltd. DIAGNOSTIC METHODS FOR ANTI-ANGIOGENIC AGENT TREATMENT
US10525127B2 (en) * 2018-03-31 2020-01-07 Femtomab P14.7 protein and uses thereof as vaccine adjuvant
AU2019286345A1 (en) * 2018-06-13 2021-01-07 The Council Of The Queensland Institute Of Medical Research Viral detection assay
JP2022524321A (ja) 2019-03-13 2022-05-02 バスキュラー バイオジェニックス リミテッド 抗腫瘍療法の方法
MX2021012398A (es) 2019-04-12 2021-11-12 Vascular Biogenics Ltd Metodos de terapia antitumoral.

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5747340A (en) 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
ATE550429T1 (de) 1996-11-20 2012-04-15 Crucell Holland Bv Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
US6649158B1 (en) 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
WO2000073432A2 (en) 1999-06-01 2000-12-07 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
IL130608A0 (en) * 1999-06-23 2000-06-01 Compugen Ltd Novel nucleic and amino acid sequence
US6867022B1 (en) * 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US7067649B2 (en) 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
MXPA03004325A (es) 2000-11-17 2004-01-26 Vascular Biogenics Ltd Promotores que muestran especificidad celular endotelial y metodos para su uso.
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
MXPA04003514A (es) 2001-10-19 2004-07-23 Vascular Biogenics Ltd Construcciones de polinucleotidos, composiciones farmaceuticas y metodos para reducir la regulacion dirigida de angionesis y terapia anticancer.
EP1576001A2 (en) * 2002-12-18 2005-09-21 Novartis AG Endothelial cell specifically binding peptides
CA2557326A1 (en) 2004-02-24 2005-09-09 Introgen Therapeutics, Inc. Combination of ad-p53 and chemotherapy for the treatment of tumours
US20080063656A1 (en) * 2004-08-09 2008-03-13 Emini Emilio A Adenoviral Vector Compositions
US20090232808A1 (en) 2005-01-28 2009-09-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
EP1942900B1 (en) * 2005-10-06 2015-06-03 Merck Sharp & Dohme Corp. Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases
EP2051988A4 (en) 2006-07-31 2010-06-02 Vascular Biogenics Ltd POLYPEPTIDES AND THESE CODING POLYNUCLEOTIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISEASES RELATED TO ISCHEMIA
EP2521776B1 (en) 2010-01-05 2016-11-02 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
JP6151515B2 (ja) 2010-01-05 2017-06-21 バスキュラー バイオジェニックス リミテッド 神経膠芽腫ｇｂｍを治療するための組成物および方法
SG10201500015TA (en) 2010-01-12 2015-02-27 Vascular Biogenics Ltd Methods of producing adenovirus vectors and viral preparations generated thereby
HUE042262T2 (hu) 2012-10-17 2019-06-28 Vascular Biogenics Ltd FAS-kimérát kifejezõ adenovírus és alkalmazása rákkezelési módszerekben

Also Published As

Publication number Publication date
EP2521776A2 (en) 2012-11-14
AU2011204405A1 (en) 2012-08-30
CA2786374A1 (en) 2011-07-14
US9567605B2 (en) 2017-02-14
JP2013516454A (ja) 2013-05-13
EP3159405A1 (en) 2017-04-26
EP2521776B1 (en) 2016-11-02
AU2011204405B2 (en) 2015-06-18
EP3159405B8 (en) 2018-11-07
DK3159405T3 (en) 2019-01-07
KR101754437B1 (ko) 2017-07-05
JP6196040B2 (ja) 2017-09-13
DK2521776T3 (en) 2017-02-13
EP3159405B1 (en) 2018-09-12
MX342641B (es) 2016-10-07
US20130280216A1 (en) 2013-10-24
JP2017186341A (ja) 2017-10-12
EP2521776A4 (en) 2013-07-31
NZ601324A (en) 2014-10-31
KR20130139741A (ko) 2013-12-23
CA2786374C (en) 2019-01-22
MX2012007849A (es) 2012-10-09
SG182367A1 (en) 2012-08-30
US20140010785A1 (en) 2014-01-09
WO2011083464A2 (en) 2011-07-14
US20130280217A1 (en) 2013-10-24
WO2011083464A3 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
SG10201500013SA (en) Methods for use of a specific anti-angiogenic adenoviral agent
TWI560172B (en) Neprilysin inhibitors
GB201116148D0 (en) Adaptor
ZA201304205B (en) Neprilysin inhibitors
ZA201403090B (en) Tropicalizing agent
ZA201304208B (en) Neprilysin inhibitors
SG10201606027VA (en) Scaffolding
EP2540790A4 (en) STAIN-RESISTANT MEDIUM
IL220850A0 (en) Pigmentation-preventing or-ameliorating agent
ZA201003952B (en) Mop
TWI562734B (en) Sense-improving agent
EP2764870A4 (en) MEANS FOR IMPROVED SENSUAL ASSESSMENT
GB2486723B (en) Shuttering
IL220797A0 (en) Methods for use of a specific anti-angiogenic adenoviral agent
PL2363354T3 (pl) Dozownik substancji czynnej
PL391725A1 (pl) Środek zwilżający
PL391723A1 (pl) Środek zwilżający
GB201004308D0 (en) New inhibitor compounds
GB201018597D0 (en) Inhibitors
GB201000631D0 (en) New use
PL392666A1 (pl) Środek gaśniczy
GB201219896D0 (en) Adaptor
HU1000688D0 (en) Use of trifluoro-phal
TWM386873U (en) Mop
GB201006352D0 (en) Bucket-less mop